Nasal ACE2 Levels and COVID-19 in Children

被引：82
|
作者：
Patel, Ankit B. [1 ]
Verma, Ashish [1 ]
机构：
[1] Brigham & Womens Hosp, Renal Div, Boston, MA USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2020年 / 323卷 / 23期
关键词：
D O I：
10.1001/jama.2020.8946
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2386 / 2387
页数：2
相关论文
共 50 条
  • [21] COVID-19 susceptibility: potential of ACE2 polymorphisms
    Mayank Chaudhary
    Egyptian Journal of Medical Human Genetics, 21
  • [22] A historical perspective on ACE2 in the COVID-19 era
    Vivek Bhalla
    Catherine A. Blish
    Andrew M. South
    Journal of Human Hypertension, 2021, 35 : 935 - 939
  • [23] Impact of ACE2 on the susceptibility and vulnerability to COVID-19
    Pringle, Kirsty G.
    Philp, Lisa K.
    JOURNAL OF ENDOCRINOLOGY, 2023, 258 (03)
  • [24] COVID-19 infection: ACE2, pregnancy and preeclampsia
    Todros, Tullia
    Masturzo, Bianca
    De Francia, Silvia
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2020, 253 : 330 - 330
  • [25] A historical perspective on ACE2 in the COVID-19 era
    Bhalla, Vivek
    Blish, Catherine A.
    South, Andrew M.
    JOURNAL OF HUMAN HYPERTENSION, 2021, 35 (10) : 935 - 939
  • [26] The therapeutic potential of targeting ACE2 in COVID-19
    Elmors, R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (18) : 9744 - 9747
  • [27] Soluble ACE2 as a potential therapy for COVID-19
    Krishnamurthy, Sudarshan
    Lockey, Richard F.
    Kolliputi, Narasaiah
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2021, 320 (03): : C279 - C281
  • [28] ACE2: At the crossroad of COVID-19 and lung cancer
    Gottschalk, Gunnar
    Knox, Konstance
    Roy, Avik
    GENE REPORTS, 2021, 23
  • [29] ACE and ACE2: insights from Drosophila and implications for COVID-19
    Herrera, Paul
    Cauchi, Ruben J.
    HELIYON, 2021, 7 (12)
  • [30] ACE2, a drug target for COVID-19 treatment?
    Yang Liu
    Huilian Huang
    Irish Journal of Medical Science (1971 -), 2023, 192 : 919 - 921
12345